MİDE KANSERİ VE ERKEN TANININ ÖNEMİ

Mide kanseri; dünyada malign tümörler arasında dördüncü sıklıkla görülür, Türkiye’de ise beşinci sıklıkla görülür. Tüm dünyada kansere bağlı ölüm nedenleri arasında ikinci sıklıktadır. Geçmiş yıllarda beş yıllık survey %15 iken günümüzde bu oran %32’dir. Bu duruma erken evrede tanı ve etkin tedavi yöntemleri temel etken olmuştur. Bu makale aromaterapinin yararları, etki mekanizması ve hemşirelik için önemini açıklamak amacıyla planlanmıştır.

GASTRİC CANCER AND THE İMPORTANCE OF EARLY DİAGNOSİS

Gastric carcinoma is the fourth-most common cancer worldwide and the fifth-most common malignancy in Turkey. Gastric cancer remains the second leading cause of cancer-related deaths worldwide. The overall 5-year survival rate is 15% in the past decade however it has risen over %32 in the recent years. The major factors influencing survival are diagnosis at early stage and more effective treatment methods.

___

  • Kitagawa Y, Dempsey DT. Stomach In: Schwartz SI. Principles of Surgery. Seventh ed. New York, 2015; 1035–98.
  • Dharmarajan S, Halpin VJ, Hawkins WG. Stomach. The Washington Manual of Surgery.5th Edition. Washington, 2008;168-80.
  • Zinner MJ, Ashley SW. Maingots Abdominal Operations. 12th ed. London, 2013:463-89.
  • Ergüney S, Yavuz N. Mide Tümörleri. Basic Surgical Dördüncü Baskı. Ankara, 2010; 1277-92.
  • De Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219-40.
  • Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230-6.
  • Patru CL, Surlin V, Georgescu I, Patru E. Current issues in gastric cancer epidemiology. Rev Med Chir Soc Med Nat Iasi. 2013;117(1):199-204.
  • Deng DJ. Progress of gastric cancer etiology: Nnitrosamides 1999s. World J Gastroenterol. 2000;6(4):613-8.
  • Du M, Wang W, Jin H, Wang Q, Ge Y,Lu J, et al. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population. Oncotarget. 2015;6(31):31255-62.
  • Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One. 2017;12(8):e0182692.
  • Hu B, El Hajj N, Sittler S, Lammert N. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251-61.
  • Nieminen A, Kokkola A, Ylä-Liedenpohja J, Louhimo J. Early gastric cancer: clinical characteristics and results of surgery. Dig Surg. 2009;26(5):378-83.
  • Gao LM. The book of Gastric Cancer: Diagnosis and treatment of gastric cancer. Transl Gastroenterol Hepatol. 2016;1:54.
  • Koç HO, Sarı YS, Bektaş H, Tunalı V, Şahin O, Özakay K, Ersöz Feyzullah E. Do we adequately diagnose early gastric cancer in Turkey. Turk J Gastroenterol. 2011;22 (3): 255-9.
  • Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, et al. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol. 2017; 2:53.
  • Şenateş E, İnce Aİ. Erken Mide Kanseri. Güncel Gastroenteroloji. 2011;15(3):161-66.
  • Sydiuk A. Current practice for gastric cancer treatment in Ukraine. Transl Gastroenterol Hepatol. 2017;2:47.
  • Yang K, Hu JK. Gastric cancer treatment: similarity and difference between China and Korea. Transl Gastroenterol Hepatol. 2017 ;2:36.
  • Kumagai K. Current Status and Future Views of Gastric Cancer Treatment in Elderly Patients. Gan To Kagaku Ryoho. 2016;43(9):1058-62.
  • Lazăr DC, Tăban S, Cornianu M, Faur A. New advances in targeted gastric cancer treatment. World J Gastroenterol. 2016;22(30):6776-99.
  • Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017 ;20 (1):1-19.
  • Mihmanlı M. Mide Kanseri ve Cerrahi Tedavisi. İstanbul, 2004;175-204.
  • Alimoğlu O, Atak İ, Eren T, Kılıç A. Robot yardımlı laparoskopik (ROYAL) gastrektomi: Olgu serisi ve literatürün gözden geçirilmesi Robot assisted laparoscopic (RAL) gastrectomy: case series and a review of the literature, Ulusal Cer Derg. 2013;29: 187-91.
  • Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol. 2016;22(11):3069-77.